Bharat Immunologicals & Biologicals Corporation Limited (BOM:524663)
India
· Delayed Price · Currency is INR 22.70
-0.21 (-0.92%)
At close: May 2, 2025
BOM:524663 Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2014 - 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '23 Sep 30, 2023 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | Mar '19 Mar 31, 2019 | 2014 - 2018 |
| Revenue | 76.5 | 446.09 | 783.88 | 853.34 | 668.37 | 836.46 | Upgrade
|
| Revenue Growth (YoY) | -89.99% | -43.09% | -8.14% | 27.68% | -20.10% | 140.37% | Upgrade
|
| Cost of Revenue | 67.76 | 391.51 | 598.48 | 813.62 | 563.2 | 707.38 | Upgrade
|
| Gross Profit | 8.74 | 54.58 | 185.4 | 39.72 | 105.17 | 129.08 | Upgrade
|
| Selling, General & Admin | 152.98 | 151.52 | 138.62 | 144.5 | 113.83 | 97.86 | Upgrade
|
| Other Operating Expenses | 54.85 | 61.56 | 96.28 | 103.61 | 93.85 | 122.06 | Upgrade
|
| Operating Expenses | 209.24 | 215.08 | 237.03 | 250.48 | 210.04 | 222.68 | Upgrade
|
| Operating Income | -200.5 | -160.5 | -51.63 | -210.76 | -104.88 | -93.6 | Upgrade
|
| Interest Expense | -74.41 | -69.63 | -51.09 | -43.64 | -40.63 | -14.57 | Upgrade
|
| Interest & Investment Income | 4.73 | 4.73 | 5.48 | 6.84 | 9.13 | 7.23 | Upgrade
|
| Currency Exchange Gain (Loss) | -1.84 | -1.84 | 4.93 | 3.74 | 1.24 | 32.65 | Upgrade
|
| Other Non Operating Income (Expenses) | 19.99 | 4.55 | -4.95 | 1.74 | -6.9 | -5.44 | Upgrade
|
| EBT Excluding Unusual Items | -252.03 | -222.68 | -97.26 | -242.08 | -142.03 | -73.74 | Upgrade
|
| Other Unusual Items | - | - | 0.39 | - | - | - | Upgrade
|
| Pretax Income | -252.03 | -222.68 | -96.87 | -242.08 | -142.03 | -73.74 | Upgrade
|
| Income Tax Expense | -67.2 | -56.29 | -9.34 | -60.95 | -39.92 | -15.8 | Upgrade
|
| Net Income | -184.83 | -166.39 | -87.54 | -181.13 | -102.11 | -57.93 | Upgrade
|
| Net Income to Common | -184.83 | -166.39 | -87.54 | -181.13 | -102.11 | -57.93 | Upgrade
|
| Shares Outstanding (Basic) | 43 | 43 | 43 | 43 | 43 | 43 | Upgrade
|
| Shares Outstanding (Diluted) | 43 | 43 | 43 | 43 | 43 | 43 | Upgrade
|
| EPS (Basic) | -4.28 | -3.85 | -2.03 | -4.19 | -2.36 | -1.34 | Upgrade
|
| EPS (Diluted) | -4.28 | -3.85 | -2.03 | -4.19 | -2.36 | -1.34 | Upgrade
|
| Free Cash Flow | - | 108.92 | -421.15 | 117.77 | 340.79 | -321.21 | Upgrade
|
| Free Cash Flow Per Share | - | 2.52 | -9.75 | 2.73 | 7.89 | -7.44 | Upgrade
|
| Gross Margin | 11.43% | 12.23% | 23.65% | 4.66% | 15.73% | 15.43% | Upgrade
|
| Operating Margin | -262.08% | -35.98% | -6.59% | -24.70% | -15.69% | -11.19% | Upgrade
|
| Profit Margin | -241.59% | -37.30% | -11.17% | -21.23% | -15.28% | -6.93% | Upgrade
|
| Free Cash Flow Margin | - | 24.42% | -53.73% | 13.80% | 50.99% | -38.40% | Upgrade
|
| EBITDA | -198.68 | -158.5 | -49.5 | -208.39 | -102.51 | -90.84 | Upgrade
|
| EBITDA Margin | -259.70% | -35.53% | -6.31% | -24.42% | -15.34% | -10.86% | Upgrade
|
| D&A For EBITDA | 1.83 | 2 | 2.13 | 2.37 | 2.37 | 2.76 | Upgrade
|
| EBIT | -200.5 | -160.5 | -51.63 | -210.76 | -104.88 | -93.6 | Upgrade
|
| EBIT Margin | -262.08% | -35.98% | -6.59% | -24.70% | -15.69% | -11.19% | Upgrade
|
| Revenue as Reported | 102.56 | 456.69 | 794.9 | 870.13 | 680.2 | 878.7 | Upgrade
|
| Advertising Expenses | - | 0.07 | 0.13 | 0.05 | 0.1 | 0.08 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.